Skip to main content

Life Sciences

Transactional – Securities & Capital Markets

  • Representing the underwriters (Cowen, SVB Leerink and Credit Suisse) in the anticipated $150M initial public offering of a biotechnology company
  • Represented NexImmune, Inc. in its $126.5M initial public offering underwritten by Barclays, Raymond James, Cantor Fitzgerald and Allen & Company
  • Represented Inhibrx, Inc. in its $136.9M initial public offering underwritten by Jefferies LLC, Credit Suisse Securities and Evercore Group
  • Represented Viela Bio, Inc. in its $172.6M initial public offering underwritten by Morgan Stanley, Goldman Sachs, Cowen and Guggenheim
  • Represented Intra-Cellular Therapies in its $295M public offering underwritten by J.P. Morgan, Leerink, Evercore, Cantor Fitzgerald, Canaccord Genuity and JMP
  • Represented G1 Therapeutics, Inc. in its $180M public offering underwritten by J.P. Morgan, Cowen, Needham & Company, Wedbush Securities Inc. and BTIG
  • Represented ImmunoGen, Inc. in its $150.7M public offering underwritten by J.P. Morgan, Goldman Sachs & Co. LLC, Cowen, Canaccord Genuity and H.C. Wainwright & Co.
  • Represented the underwriters in the $188.5M public offering of Adverum Biotechnologies, Inc. underwritten by SVB Leerink LLC, Goldman Sachs & Co. LLC, Piper Sandler & Co., and Cowen and Company, LLC
  • Represented the underwriters in the $492M public offering of Acceleron Pharma Inc. underwritten by JP Morgan Securities, SVB Leerink, Cowen and Company, Barclays, Credit Suisse and Piper Sandler
  • Represented the underwriters in the $152M public offering of Mersana Therapeutics underwritten by Cowen and Company, SVB Leerink, Wedbush PacGrow, Baird and H.C. Wainwright & Co.

Transactional – SPACs

  • Represented Butterfly Network, Inc. (NYSE: BFLY), an innovative social impact digital health company, in its $1.5B business combination with the SPAC, Longview Acquisition Corp.
  • Represented Locust Walk Acquisition Corp. in its business combination with eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a biopharmaceutical company
  • Represented Vicarious Surgical Inc. (NYSE: RBOT), a next-generation surgical robotics company, in its $1.1B business combination with the SPAC, D8 Holdings Corp.
  • Represented Hyperfine, Inc. (NASDAQ:HYPR), a medical device company that created a portable MRI system, in its $580M business combination with Liminal Sciences, Inc. and the SPAC, HealthCor Catalio Acquisition Corp.
  • Represented DermTech, Inc. (NASDAQ: DMTK), a biotech company focused on precision dermatology, in its $440M business combination with the SPAC, Constellation Alpha Capital Corp.

Transactional – Mergers & Acquisitions

  • Represented Azenta Life Sciences (NASDAQ: AZTA) (formerly Brooks Automation, Inc.), a leading provider of life sciences solutions worldwide, in the sale of its Semiconductor Solutions business to private equity firm Thomas H. Lee Partners, L.P. for $3B in cash
  • Represented Viela Bio, Inc. (Nasdaq: VIE), a biotechnology company, in its $3.05B sale to Horizon Therapeutics plc (Nasdaq: HZNP), a specialty and generic drug manufacturing company
  • Represented QIAGEN N.V. (NYSE: QGEN), a Germany-based provider of life science and molecular diagnostic solutions, in multiple transactions, including its cross-border acquisition of NeuMoDx Molecular, Inc., a US-based company that designs and develops molecular diagnostic solutions for hospital and clinical reference laboratories, its acquisition of the digital pcr assets of Formulatrix, Inc., its strategic partnership with NeuMoDx Molecular, Inc., its acquisition of Ingenuity Systems, Inc., as well as its acquisition of SA Biosciences Corporation
  • Represented Myriad Genetics, Inc. (NASDAQ: MYGN), a molecular diagnostic company, in multiple acquisitions, including its sale of Myriad RBM, Inc., which specializes in contract research services for the pharmaceutical industry, to Q2 Solutions, its acquisition of Counsyl, its acquisition of Assurex Health, as well as its acquisition of Crescendo Bioscience, Inc.
  • Represented Walk Vascular, LLC, a commercial-stage medical device company with a minimally invasive mechanical aspiration thrombectomy system designed to remove peripheral blood clots, in its sale to Abbott (NYSE: ABT)
  • Represented Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, in its acquisition of UmanDiagnostics AB, the world’s leading Nf-L antibody supplier
  • Represented Censa Pharmaceuticals, Inc., a biopharmaceutical company, in its sale to PTC Therapeutics, Inc. (NASDAQ: PTCT), a global biopharmaceutical company
  • Represented Biogen Inc. (NASDAQ: BIIB), a biotechnology company, in the $900M sale of a biologics manufacturing facility to FujiFilm Corporation, a photography and imaging company
  • Represented Orgenesis Inc. (NASDAQ: ORGS), in the sale of its stake in its Mastercell Global, Inc. subsidiary to Catalent Pharma Solutions for a total purchase price of $315M, of which Orgenesis received approximately $127M of net proceeds
  • Represented FloDesign Sonics, Inc., an acoustic cell processing platform developer for the industrialization of cell and gene therapy manufacturing, in its sale to EMD Millipore Corporation
  • Represented Philips Healthcare in connection with dozens of mergers and acquisitions and other strategic transactions in the areas of diagnostic imaging and ultrasound, image-guided therapy, patient care and monitoring solutions, sleep and respiratory care, therapeutic temperature management, healthcare informatics and population health management, and health and wellness

Transactional – Venture Capital

  • Represented Cardurion Pharmaceuticals, Inc. in its private investment of up to $300M from Bain Capital Life Sciences and Bain Capital Private Equity
  • Investor-side representation in the $25M Series D financing of a cancer therapeutic company led by Matrix Capital Management
  • Investor-side representation in the $70M Series B financing of Oncorus, Inc. led by Cowen and Company and Perceptive Life Sciences
  • Investor-side representation in the $82.5M Series B financing of Repare, Inc. led by Cowen Healthcare Investments, Orbimed, Redmile, Versant, and MPM Bioventures
  • Represented Viela Bio, Inc. in its $75M Series B financing led by HBM Healthcare Investments, Viking Global Investors, Cormorant Asset Management, Terra Magnum Capital Partners, Goldman Sachs, Barer & Son Capital, and Temasek
  • Represented Aura Biosciences, Inc. in its $40M Series D financing led by Meicxi Ventures, Arix Bioscience, Lundbeck, Advent Venture Partners, Chiesi Ventures, and Ysios Capital
  • Investor-side representation in the $235M Series A financing of AskBio led by Vida Ventures
  • Investor-side representation in the $15M Series C-1 financing of SPR Therapeutics led by Sunrise Management Services
  • Represented Vedanta Biosciences in its $26.7M Series C preferred stock financing led by the Bill & Melissa Gates Foundation, PureTech Health, Invesco, and Bristol-Myers Squibb
  • Investor-side representation in the $40M Series B financing of Cadent Therapeutics, Inc. led by Cowen Healthcare Investments, Atlas Venture, Qiming Venture Partners, Access Industries, Clal Biotechnology Industries, and Novartis Institutes for Biomedical Research
  • Represented Black Diamond Therapeutics Inc. in its $85M Series B Preferred financing led by NEA, Versant Ventures, and RA Capital

Patent Litigation and IPRs

  • Represented plaintiffs Kowa Company, Ltd., Kowa Pharmaceuticals America, Inc. and Nissan Chemical Industries, Ltd. in litigation which involved compound, formulation, and polymorph patents directed toward quinoline-type mevalonolactones (or, pitavastatin calcium) relating to the drug product Livalo®. Several of the cases successfully resolved pre-trial, and after a 10-day trial plaintiffs prevailed on all issues in two court decisions against the remaining defendants, Amneal and Apotex. Mintz represents Kowa and Nissan in the appeal filed by Amneal and Apotex in the Federal Circuit. The team also defeated institution of three inter partes reviews filed by generic manufacturer defendants in these cases.
  • Defended Enzymatics against claims of trade secrets theft and patent infringement brought by three plaintiffs in a case involving nucleic acid ligands. Resulted in favorable settlement for our client.
  • Takeda Chemical Industries Ltd. v. Mylan and Alphapharm; 417 F. Supp. 2d 341, (S.D.N.Y. 2006); aff'd, 492 F.3d 1350 (Fed. Cir. 2007); cert. denied. 552 U.S. 1295 (2008) - Post-KSR case interpreting Supreme Court approach to obviousness and upholding non-obviousness of important pharmaceutical advances.


  • Counseled a large clinical diagnostics company on the design and implementation of a tissue banking and outcomes research program, including acquisition of clinical data within regulatory confines to support an outcomes research program.
  • Provided strategic counsel to a start-up medical application company that has devised a method to detect mild cognitive impairment as a precursor to more significant cognitive diseases.
  • Advised on legal and regulatory issues surrounding market launch of a software solution to gather patient data from peripheral devices and coordinate a communication and management platform with their physician, including licensing arrangements, clinical study agreements, and quality and supply agreements.
  • Counseled a pharmaceutical company on the post-mortem acquisition of tissue samples and associated clinical data to support its research program.
  • Counseled a publically traded medical device company on risk management advice and helped them manage multiple significant adverse events following suspension of trial by the FDA.
  • Participated in marketing and labeling pre-launch team, working side by side with biological client team to craft marketing messages and product labeling for product launch.
  • Advised a medical device company on possible FDA regulation of treatment of mobile wireless applications as medical devices.
  • Represent a national IVF clinic and management provider in drug delivery, pharmacy relationships, and delivery of care issues.
  • Advised the Institutional Animal Care and Use Committee of a large, academic medical center on a variety of preclinical studies, including studies involving a primate model.
  • Guided a medical device manufacturer through multiple FDA inspections and developed effective and sustainable corrective actions to address deficiencies and avoid focused FDA enforcement.
  • Advise innovative drug development client on regulatory strategy following Phase II clinical study data analysis.
  • Conducted a regulatory assessment and classification of software product used to support monitoring and management of patients with chronic obstructive pulmonary disorder.
  • Assisted a private company in the establishment of a stem cell research oversight committee to support its stem cell research program, in compliance with state and federal standards.
  • Serve as general counsel to a 501(c)(3) organization engaged in research and education in peripheral vascular disease, including advice on the initial structure and ongoing management of its entire research program; drafting, reviewing, and negotiating agreements and consent forms; and assisting with audits and other inquiries.


  • Represented a global pharmaceutical manufacturer in a highly publicized antitrust MDL class action antitrust litigation, which was the first alleged pharmaceutical “pay-for-delay” case to go to trial since the Supreme Court articulated a new controlling legal standard in its 2013 decision in FTC v. Actavis. Case settled on favorable terms.
  • Served as counsel for a global pharmaceutical company in a lawsuit alleging that a group of pharmaceutical manufacturers conspired to overstate the average wholesale price (“AWP”) for prescription drugs covered by the Medicare program. Plaintiffs advanced claims under §§ 1 and 2 of the Sherman Act and the RICO Act. Through our advocacy, we convinced plaintiffs to drop their claims against our client in their consolidated amended complaint, thereby concluding involvement in the matter without any liability.
  • Won an arbitration award, following over a week of trial, completely dismissing all claims of material breach of a collaboration agreement that would have deprived our client, an international biotech company, of its fifty percent interest in a billion-dollar drug.
  • Served as Lead California Counsel and on National Trial Team for large pharmaceutical client in massive products liability litigation involving company’s voluntary withdrawal of blockbuster nonsteroidal anti-inflammatory drug alleged to have caused heart attack, strokes and other injuries in thousands of users from the market. Participated in several bellwether trials that went to verdict in NJ and CA.
  • Served for more than two decades as national products liability and lead trial counsel for national medical device manufacturer with responsibility for handling, supervising, managing and/or directing the defense of their significant products liability matters and providing general advice regarding risk management, CAPA, recalls, pre-litigation strategy, litigation prevention and regulatory issues relating to their various divisions and product lines. Also supervised local counsel throughout the country and participated in trials in multiple venues.
  • Defended a public pharmaceutical company and its officers against 10(b) claims and Section 11 claims arising out of a secondary public offering and successfully obtained a motion to dismiss these claims on behalf of our client.
  • Represented Vertex Pharmaceuticals, Inc. in a decision crystalizing the standard required to plead scienter in securities fraud cases, the First Circuit affirmed the dismissal of a securities class action complaint filed against Vertex and the company’s senior executives by Local No. 8 IBEW Retirement Plan and Trust.  This decision ends four years of litigation defending against plaintiff’s false and unfounded allegations that Vertex’s disclosures regarding the results of clinical trials assessing the safety and efficacy of the company’s combination drug therapy for the treatment of patients with cystic fibrosis violated the federal securities laws. We successfully rebuffed plaintiffs twice in the District Court, ultimately securing victory in the First Circuit.
  • Served as national coordinating and trial counsel for large pharmaceutical company for litigation involving use of synthetic hormones and claims it acted as a trans-placental carcinogen and teratogen and was associated with the development of gynecologic cancers and birth defects in claimants exposed in utero. Tried multiple cases to verdict in CT, PA, CA and other jurisdictions.
  • Represented Geneius Biotechnology, Inc in a dispute with a minority shareholder that attempted to gain control of the company. In an expedited matter, we served as lead trial counsel in the Delaware Chancery Court and secured a total victory for the client.

Patent Prosecution & Strategic Counseling

  • Conducted a freedom to operate assessment for a client which produces a clinical diagnostic product, essentially a lab-on-a-chip which provides for point of care testing for a wide range of infections. Most such tests have to be conducted at a central laboratory, which increases expense and causes a significant wait for results. The company's product allows treatment professionals to carry out testing on-site. We reviewed numerous third-party patents to advise the company that it had freedom to operate.
  • Conducted a broad scope due diligence for a medical device manufacturer as it considered investing in a company operating in the electrical nerve stimulation space. This effort involved understanding the technology and the details of future, to-be-developed products. It was necessary to assess the potential for the company to have freedom to market these future products. In doing so, detailed evaluations of some patents were necessary. Our study also assessed the quality of the patent protection in place at the investee, with the goal of determining the effectiveness of the portfolio to prevent third parties from successfully marketing competing technology. We ultimately advised our client that the target company had clearance to operate and the client made the investment.
  • Advised medical device client on developing and implementing a post-litigation strategy. Having lost a patent litigation (in which they were represented by another law firm), Mintz attorneys helped the company assess whether they could keep their product on the market during the appeal process. We then provided advice on how to create possible design-arounds for the product to ensure it was clear of infringing the patents at issue, in the event that the appeal was unsuccessful.
  • Represent a leading nonprofit clinical research center, hospital, and graduate school which is a founding member of the National Comprehensive Cancer Network. The center is focused on the treatment of cancer, diabetes, and other life-threatening diseases, and has been designated as a comprehensive cancer center, the highest acknowledgment granted by the National Cancer Institute. The firm's attorneys have represented the hospital in developing and implementing strategies for procuring patents in a variety of chemical and biomedical technologies.
  • We are trusted by a high-profile San Diego-based vision-focused medical device incubator with helping to assess and develop the patent strategies of its portfolio companies, and have been key legal counsel in recent successes of its portfolio companies. In 2016 and 2017, two of the incubator's companies were acquired by global corporations.
  • Represent a leading worldwide provider of transfusion and transplantation diagnostic products, including instruments, reagents, antibodies, and molecular assays, serving as go-to counsel on both patent prosecution and technology- or IP-based commercial transactions. The company, which grew significantly in 2015 through a series of major acquisitions on which they were represented by members of the Mintz team, trusts the firm for insights into the value of the IP held by potential acquisition targets, including not only what is covered, but also the quality of the protections provided by the portfolio considering other competition in the marketplace. Our relationship attorney for this client serves as Chairman of the company's IP Management Committee, helping the client integrate technologies from acquisitions, including developing the offensive and defensive strategies for those patent families in order to maximize their marketplace value.
Case Study
Mintz advised client ArriVent BioPharma, a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, on its upsized $175 million IPO on Nasdaq.
Case Study
Mintz represented ArriVent Biopharma in a $155 Million Series B financing led by Sofinnova Investments and General Catalyst to fund studies of the company's EGFR kinase inhibitor furmonertinib. Members Ed Pease and Private Equity Practice Co-Chair Matthew Simpson led the Mintz team's work on the transaction.
Case Study
When Daré Bioscience Operations, Inc. first became a Mintz client, it was a private health care company working to develop innovative product candidates in women’s reproductive health. Due to the significant expenses associated with product development and regulatory compliance for innovative drug, device, and combination products, the San Diego-based company sought to raise capital through entering the public markets. Since becoming a public company, Daré Bioscience has in-licensed multiple exciting product candidates focused on women’s sexual health, vaginal health, fertility, and contraception and prioritized a goal of achieving FDA marketing approval for one or more products.
Case Study
Mintz’s client received 100% of the fees we requested on his behalf and was awarded $50,000 in sanctions when the arbitrator concluded the company’s counterclaims were frivolous.
Case Study
Mintz litigators achieved a complete victory on behalf of our client Keryx Biopharmaceuticals in a putative securities class action case seeking over $100 million in damages.
Case Study
Mintz and Licensing & Collaborations Practice Member John Cheney have represented BeiGene in numerous licensing transactions, including strategic collaborations with Amgen, Mirati Therapeutics, and Celgene, among others.
Case Study
Mintz successfully achieved a nine figure arbitration award on behalf of a Boston-based biotechnology company before the International Chamber of Commerce.
Case Study
Mintz is advising Vicarious Surgical Inc., a robotics company developing technology that combines human-like surgical robots and virtual reality to perform minimally invasive surgery, in a pending merger with special purpose acquisition company D8 Holdings Corp. that is expected to deliver up to $460 million in gross proceeds.
Case Study
Check out UNITED NOTIONS, a new report on M&A activity in the life sciences sector. Produced in collaboration with Mergermarket, the report provides a comprehensive look at the health of deal activity in the industry and an insightful view of current trends as compared to a year ago.
Case Study
Mintz analyzed PitchBook data to produce an in-depth report on the record rise in special purpose acquisition company (SPAC) fundraising in the US since 2020 and the recent increase in SPAC merger activity. We also explore how SPACs could evolve and litigation challenges to SPAC IPOs and transactions.
Case Study
Mintz is acting as legal advisor to Quantum-SI Incorporated, developer of a pioneering semiconductor chip to sequence proteins, in its proposed business combination with HighCape Capital Acquisition Corp., a special purpose acquisition company (SPAC) sponsored by growth equity investment firm HighCape Capital LP.
Case Study
Mintz served as legal advisor to Butterfly Network Inc., an innovative digital health company, in its merger with Longview Acquisition Corp., a special purpose acquisition company (SPAC) sponsored by Glenview Capital Management, LLC.
Case Study
Mintz represented ImmunoGen in a $200 million non-dilutive royalty transaction of its interest in Kadcyla with funds managed by TPG Special Situation Partners.
Case Study
In the first transaction of its kind, Mintz represented Intarcia Therapeutics in two synthetic royalty financings with an equity conversion option valued at $5.5B for ITCA 650.
Case Study
Mintz represented ARIAD Pharmaceuticals in a synthetic royalty financing in which PDL BioPharma agreed to provide up to $200 million in revenue interest financing to ARIAD in exchange for royalties on worldwide net revenues of Iclusig (ponatinib).
Case Study
Mintz represented Spero Therapeutics, a clinical-stage biopharmaceutical company developing treatments for drug-resistant bacterial infections, in a September 2020 underwritten public offering that netted $80 million in gross proceeds before the deduction of underwriting discounts and commissions.
Case Study
Mintz advised Glia, LLC on its successful bid to obtain orphan drug status from the FDA for its topical gel to treat ocular Graft-versus-Host Disease. The disease can affect stem cell or bone marrow transplant recipients and cause intense eye pain, ocular degeneration, and blindness.
Case Study
Mintz represented Massachusetts General Hospital and Partners HealthCare in a deal that enables them to monetize part of their royalty interests in Entyvio, an antibody used to treat digestive diseases, to invest in research. Royalty Pharma paid $94 million in the true sale roll-up transaction.
Case Study
Mintz and Mergermarket produced a comprehensive report on recent M&A activity in the life sciences sector. We asked 100 US-based executives to share what motivated their latest transaction and their post-closing integration experiences.
Case Study
Mintz provides ongoing counsel to global biotech company in e-data discovery in a series of nationwide product liability cases related to its global franchise of marketed products.

Case Study
Mintz’s E-Data Consulting Group counseled a large physician’s network and nonprofit hospital in complex negotiations with the Federal Trade Commission in relation to a proposed merger with another midsize physician’s network and hospital.
Case Study
Mintz successfully led a national diagnostics company through a series of informal investigative inquiries from the Department of Justice and formal responses to subpoenas issued by the Office of Inspector General.
Case Study
After a lender abandoned our client’s financing transaction over concerns related to COVID-19, Mintz negotiated a convertible note financing with another investor — providing the client with up to $25M to pursue commercialization of its lead product.
Case Study
Mintz helped patent prosecution client Glycosyn defend its exclusive patent rights against the company's largest competitor, a global company selling infringing ingredients used in baby formula.
Case Study
Mintz represented Synlogic in an $80 million financing from Ginkgo Bioworks and the parties' related collaboration to expand development of Synlogic’s Synthetic Biotic medicines. Mintz previously helped Synlogic raise over $200 million in capital, plus another $40 million through a reverse merger.
Case Study
Mintz represented Vida Ventures on the $600 million fundraise for its Vida II fund, which will be used to further the firm’s life sciences platform. Founded less than two years ago, Vida now has approximately $1 billion under management.
Case Study
After helping Spero raise over $200 million, Mintz represented the biopharmaceutical company in its collaboration with the Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis (Mtb).
Case Study
Mintz advised biopharma company Spero Therapeutics on an agreement with Everest Medicines regarding the development and commercialization of a product to treat multidrug-resistant bacterial infections and option to license another.
Case Study
Mintz secured dismissal of a securities fraud case against biopharmaceutical company Neurotrope. Mintz argued that securities laws do not require disclosure of the statistical methodology behind announced clinical trial results.
Case Study
Mintz represented ImmunoGen, a maker of targeted anticancer therapeutics, in a transaction that netted $194 million. The deal provided ImmunoGen with cash and liquid assets in exchange for assigning certain royalty revenues for the breast cancer treatment Kadcyla to TPG Special Situations Partners.
Case Study
In July 2018 Mintz represented Spero Therapeutics, a multi-asset clinical stage biopharmaceutical company, in its underwritten public offering. The offering included 3,780,000 shares of its common stock and 2,220 shares of its non-voting Series A Convertible Preferred Stock, with the gross proceeds to Spero being $75M prior to the deduction of any underwriting discounts and commissions.
Case Study
Mintz steered precision health company Quanterix Corporation through a $73.7 million initial public offering (IPO). The firm’s Securities & Capital Markets Practice advised Quanterix on the Securities and Exchange Commission review process as well as pricing and timing of the offering.
Case Study
Mintz transactional and health regulatory professionals represented clinical-stage oncology company G1 Therapeutics in its $108.6 million initial public offering (IPO).
Case Study
In federal and state cases alleging a large pharmaceutical client and its co-developer failed to adequately warn regarding the risk of personal injury, Mintz delivered wins on every substantive issue, in every case, in every jurisdiction.
Case Study
Professionals in Mintz's Patent Prosecution & Strategic Counseling Practice advise Roche Molecular Systems on various patent matters. Mintz has managed the client’s patent portfolio since Roche Molecular acquired Ariosa Diagnostics and its non-invasive prenatal test “Harmony.
Case Study
For Kowa Pharmaceuticals and Nissan Chemical, Mintz sued nine generic drug makers that had filed Abbreviated New Drug Applications (ANDA) with the FDA. The court upheld the validity and infringement of all asserted claims in two patents for the cholesterol drug Livalo®.
Case Study
Mintz serves as general counsel to a privately held pharmaceutical R&D company focused on inflammatory, metabolic, and affective disorders. Mintz handles the company’s corporate, transactional, and IP work, including supporting the company’s preclinical and clinical research program.
Case Study
Mintz has represented oncology-focused biotherapeutic company Inhibrx LP since its inception. Mintz attorneys have advised Inhibrx on licensing deals and financing deals involving unusual corporate and tax structuring and international aspects.
Case Study
Mintz secured two MA federal court wins and one at the First Circuit for Vertex Pharmaceuticals, Inc. and several senior executives in a securities case about clinical trial result disclosures. The decision clarified the First Circuit standard for pleading scienter in securities fraud cases.
Case Study
Mintz represented BeiGene, Ltd. in its global strategic collaboration with Celgene Corporation to develop and commercialize BeiGene’s cell death protein 1 (PD-1) inhibitor tislelizumab (BGB-A317) for patients with solid tumor cancers. Mintz also assists BeiGene with licensing transactions.
Case Study
Mintz represented clinical-stage biopharmaceutical company Naurex Inc., which develops therapies for central nervous system disorders, in its acquisition by global pharmaceutical company Allergan PLC for $560 million plus potential milestone payments. Naurex’s platform was spun out into a new company.
Case Study
Mintz is defending a major diagnostics company in a False Claims Act qui tam case filed by a former employee. The Department of Justice declined to intervene in the case, which involves allegations of managed care fraud. Mintz has filed a motion to dismiss and objections to discovery request
Case Study
Mintz secured a full release of a biopharmaceutical company in a Louisiana state court case over alleged inflated drug price reporting. The client agreed to a nuisance value settlement of the case, resolving claims its actions cost the state’s Medicaid program more than $20 million.
Case Study
Mintz provides FDA, data privacy, and clinical compliance advice to a publicly traded biotechnology company developing nucleic acid therapeutic candidates for rare genetic diseases, including Huntington’s disease and Duchenne Muscular Dystrophy. Mintz also helped the client expand its R&D program.
Case Study
Mintz is helping a manufacturer and distributor of device systems used in wound treatment pursue Medicare and Medicaid coverage options throughout the country, including negotiating coding. Mintz attorneys met with the Centers for Medicare & Medicaid Services (CMS) regarding scope of coverage.
Case Study
Mintz serves as national trial and coordinating counsel in two mass tort litigations against a surgeon involved in the design of two implantable orthopedic devices. An early trial result facilitated a national settlement that resolved most of the individual cases in one mass tort.
Case Study
Mintz successfully mediated a dispute relating to medical device company Invivo Corp.’s retention of an $850,000 holdback reserve in its acquisition of Hologic, Inc.’s Sentinelle, an MRI coil product line. Mintz argued that Invivo suffered monetary losses due to Hologic’s breaches and inaccuracies.
Case Study
Mintz served as national coordinating and lead trial counsel for a Fortune 500 medical device company in products liability mass torts. Mintz used a national settlement program in one litigation. Several published appellate decisions in another led to dismissals and favorable settlements.
Case Study
Mintz served on national trial teams for a major pharmaceutical company in defending over 50,000 individual lawsuits, federal multidistrict litigation, and statewide coordinated proceedings alleging personal injury and wrongful death. Mintz's trial results facilitated the $4.85 billion settlement.
Case Study
Mintz helped two in-house Johnson & Johnson attorneys conduct due diligence for J&J’s $4.325 billion acquisition of Abbott Medical Optics (AMO). Mintz attorneys assessed AMO’s patent portfolio, license and settlement agreements, and patent litigations and made freedom-to-operate assessments.
Case Study
Mintz protected clients’ patents related to the cholesterol drug Livalo®. Mintz defended against three IPRs filed by generic manufacturers that had filed Abbreviated New Drug Applications (ANDA) with the FDA and secured Patent Trial and Appeal Board denials of institution of the generic companies’ IPR petitions.
Case Study
Mintz helped women’s reproductive health care company Daré Bioscience Operations, Inc. become a wholly owned subsidiary of Cerulean and a publicly traded company named Daré Bioscience, Inc. The innovative deal utilized a variation of a reverse merger into a publicly traded fallen-angel.
Case Study
Mintz’s work for synthetic biotic company Synlogic Inc. has included raising over $100 million in three VC financing rounds. Mintz attorneys also helped Synlogic form a multiyear global R&D collaboration with AbbVie and raise more than $40 million in an IPO via a reverse merger with Mirna Therapeutics.